LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands. The oral and poster presentations at ERS 2011 will highlight the potential of PUR118 as an effective treatment for acute exacerbations of the lung associated with chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), and serious respiratory infections. PUR118, the lead clinical candidate using Pulmatrix’s proprietary iCALM technology, is currently in Phase 1b human clinical trials for COPD.
